Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00925106 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics Of Celecoxib Test Formulations
A Phase 1 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00925106 is a Phase 1 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 16 participants.
The verdict
NCT00925106, a Phase 1 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected to provide more favorable bioavailability characteristics than the present commercial formulation.
Interventions
- DRUG Celebrex capsule
- DRUG Test formulation D1
- DRUG Test formulation D2
- DRUG Test formulation D3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00925106
The ClinicalTrials.gov registry entry for NCT00925106 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Celebrex capsule is the first listed.
NCT00925106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00925106 about?
NCT00925106 is a clinical study titled "Pharmacokinetics Of Celecoxib Test Formulations". The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected to provide more favorable bioavailability characteristics than the present commercial formulation.
What is the current status of trial NCT00925106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-07. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00925106?
The interventions under investigation include: Celebrex capsule (DRUG), Test formulation D1 (DRUG), Test formulation D2 (DRUG), Test formulation D3 (DRUG).
Who is sponsoring clinical trial NCT00925106?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.